Gastrointestinal Stromal Tumor Clinical Trial
Official title:
A Phase II Study of Gleevec (Imatinib Mesylate, NSC 716051 Formerly STI571) in Children With Refractory or Relapsed Solid Tumors
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have relapsed or refractory solid tumors of childhood. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
Status | Completed |
Enrollment | 100 |
Est. completion date | December 2005 |
Est. primary completion date | December 2005 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A to 30 Years |
Eligibility |
Inclusion Criteria: - Histologically confirmed solid tumors including the following: - Ewing's sarcoma - Bone or soft tissue primitive neuroectodermal tumor - Osteosarcoma - Neuroblastoma - Desmoplastic small round cell tumor - Synovial cell sarcoma - Gastrointestinal stromal tumor (GIST) - Metastatic pulmonary disease eligible - No pleural effusion of any size or definite radiologic evidence of pleural-based disease - Recurrent or refractory to conventional therapy - GIST eligible at initial presentation - Tumor tissue blocks must be available - At least 1 measurable lesion - At least 20 mm by conventional techniques - At least 10 mm by spiral CT scan - Lesions assessable only by radionuclide scan are not considered measurable - Performance status - Lansky 50-100% (= 10 years of age) - Performance status - Karnofsky 50-100% (> 10 years of age) - At least 2 months - Absolute neutrophil count = 1,000/mm^3* - Platelet count = 75,000/mm^3* (transfusion independent) - Hemoglobin = 8.0 g/dL* (RBC transfusions allowed) - Bilirubin = 1.5 times upper limit of normal (ULN) - ALT = 2.5 times ULN - INR < 1.5 - PTT = ULN - Fibrinogen = lower limit of normal - Creatinine normal for age - Glomerular filtration rate = 70 mL/min - No uncontrolled infection - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective barrier contraception - At least 1 week since prior biologic therapy or immunotherapy and recovered - At least 1 week since prior growth factors - No concurrent immunomodulating agents - At least 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered - No concurrent chemotherapy - No concurrent steroids - Recovered from prior radiotherapy - At least 2 weeks since prior local palliative radiotherapy (small port) - At least 3 months since prior craniospinal radiotherapy or radiotherapy to 50% or more of pelvis - At least 6 weeks since other prior substantial bone marrow radiation - No concurrent radiotherapy during first course of treatment - Concurrent palliative radiotherapy to local painful lesions allowed after first course of treatment provided there is no evidence of disease progression and at least 1 measurable lesion remains outside radiation port - No concurrent therapeutic doses of warfarin - No concurrent anticonvulsants that induce the cytochrome p450 enzyme system (e.g., phenytoin, carbamazepine, and phenobarbital) - Concurrent benzodiazepines and gabapentin allowed - Concurrent low-molecular weight heparin allowed |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Children's Oncology Group | Arcadia | California |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response rate, determined using the RECIST criteria | 95% confidence interval will be computed. | Up to 2 years | No |
Primary | Toxicity reported using the CTC version 2.0 | Up to 2 years | Yes | |
Secondary | Time to disease progression | Calculated by the method of Kaplan and Meier. | Up to 2 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04933669 -
Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
|
Phase 2 | |
Completed |
NCT01769248 -
Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
|
N/A | |
Completed |
NCT01774162 -
EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration
|
N/A | |
Completed |
NCT01110668 -
Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
|
Phase 2 | |
Terminated |
NCT00091078 -
Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00025246 -
Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
|
Phase 2 | |
Active, not recruiting |
NCT00265798 -
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
|
Phase 2 | |
Recruiting |
NCT04143048 -
A Study on Non-invasive Early Diagnosis of Gastrointestinal Stromal Tumors and Differentiation of Benign and Malignant Nodules
|
||
Recruiting |
NCT02931981 -
Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor
|
N/A | |
Not yet recruiting |
NCT02576080 -
Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index
|
Phase 3 | |
Recruiting |
NCT01389583 -
A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients
|
Phase 2 | |
Recruiting |
NCT00777504 -
Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors
|
Phase 4 | |
Completed |
NCT00769782 -
Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor
|
Phase 2 | |
Completed |
NCT00764595 -
Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor
|
Phase 2 | |
Completed |
NCT00098579 -
Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery
|
Phase 1 | |
Completed |
NCT00005862 -
SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas
|
Phase 2 | |
Completed |
NCT00004895 -
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
|
Phase 2 | |
Recruiting |
NCT02776878 -
A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
|
N/A | |
Completed |
NCT01751919 -
A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)
|
Phase 1 | |
Completed |
NCT01267695 -
Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
|
Phase 2 |